Navigation Links
Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa

Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant... -- ABBOTT PARK, Ill., Nov. 8, 2010 /PRNewswire-FirstCall/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Infection Control, Medical Pharmaceuticals, Pharmaceuticals, Joint Ventures, Children-related News, Domestic Policy, Corporate Social Responsibility Click to view news release full screen  

Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa


ABBOTT PARK, Ill., Nov. 8, 2010 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and the Clinton Health Access Initiative (CHAI) have joined forces to provide HIV testing to infants in all countries working in partnership with the CHAI.  A key focus of this cooperation will be sub-Saharan Africa, which the World Health Organization estimates to account for 90 percent of global HIV infections in children.

Under terms of the agreement, Abbott will supply its RealTime HIV-1 Qualitative test kits to healthcare facilities.  The test is currently available for research use only and is expected to be CE marked (Conformite Europeene) by January 2011.  Abbott will also offer the capability to collect and process samples using dried blood spots (DBS).  The use of DBS for specimen collection eliminates the need for refrigeration of specimens.

In addition to the supply of HIV tests and DBS sample collection for research use, Abbott is collaborating with CHAI to develop a "turn-key" laboratory solution, including training protocols on instruments that will be used to establish fully functioning molecular diagnostic laboratories in regions where such facilities do not currently exist.

"We're pleased to be collaborating with the CHAI in its proactive outreach effort to test infants in developing nations for HIV," said Stafford O'Kelly, head of Abbott's molecular diagnostics business.  "Accurate and accessible HIV testing, particularly for diagnosis of HIV/AIDS in infants less than 18 months of age, is essential for optimal management and treatment of the disease."

About Abbott Molecular Abbott Molecular,, is an emerging leader in molecular diagnostics - the analysis of DNA, RNA, and proteins at the molecular level.  Abbott Molecular's instruments and assays are used for early detection and diagnosis of disease, to influence the selection of appropriate therapies and as an aid in monitoring disease progression.

About Abbott Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs nearly 90,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at


Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
2. Abbott Again Recognized for Environmental Initiatives in Illinois
3. Abbott Statement: Abbott Provides Support for Cholera Relief Efforts in Haiti
4. Abbott to Voluntarily Withdraw Meridia® (Sibutramine) in the U.S.
5. Abbott Laboratories Agrees to Withdraw Its Obesity Drug Meridia
6. Abbott Named One of the Top Employers in the Biotech and Pharmaceutical Industry by Science Magazine
7. Abbott Receives FDA Market Clearance for Next-Generation Contact Lens Disinfecting Solution
8. Abbotts XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
9. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
10. Abbotts Fully Bioresorbable Vascular Scaffold Technology Continues to Demonstrate Strong Clinical Results
11. The Deal Names Abbott Top Dealmaker for Third Consecutive Year
Post Your Comments:
(Date:12/1/2015)... -- CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical ... that it has reached its enrollment target of 400 ... trial of aldoxorubicin in patients with previously treated soft ... in Q1 2016. The Phase 3 trial is a randomized, ... from the FDA at 79 sites in ...
(Date:12/1/2015)... 2015  The migration to value-based care will ... plans that help patients stay healthy and reduce ... digitally enabled, incorporate care guidelines and be reflective ... will also allow all stakeholders to collaborate across ... optimal. That is the vision, however, research by ...
(Date:12/1/2015)... -- --> --> ... (NKI-AVL), among the world,s largest and most prestigious ... Icon™, the company,s latest generation stereotactic radiosurgery system ... --> With the option to use ... Knife Icon offers greatly enhanced flexibility in how ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 -- InstantLabs ... company’s growing product line of food safety and seafood fraud prevention tools. , ... – allow InstantLabs to offer fast, reliable species identification for the four most ...
(Date:12/1/2015)... ... December 01, 2015 , ... It’s official: Tattoo taboo is a thing of ... greater among Millennials (a whopping one in three aged 18 to 25 is inked). ... dissatisfied with their ink. In fact, RealSelf , the world’s largest community for ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance ... imaging is the focus of numerous abstracts accepted for presentation here, at the ... Nine abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates mobile imaging ... owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they are demonstrating ... North America (RSNA) 2015 annual meeting through December 3 in Chicago, Illinois, at ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... today announced it has been awarded a fixed price per sprint agile development ... contract, valued at $34 million over five years, provides software engineering, infrastructure, as ...
Breaking Medicine News(10 mins):